Molecular Testing in EC

CME

Molecular Testing for Key Biomarkers in Advanced Endometrial Cancer

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: November 02, 2023

Expiration: November 01, 2024

Hye Sook Chon
Hye Sook Chon, MD
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

Introduction

In this module, Hye Sook Chon, MD, discusses the latest guidance and data on molecular testing for established and emerging biomarkers, along with their prognostic and/or predictive roles, in patients with advanced endometrial cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. One question will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Poll

For those providing patient care, how many patients with endometrial cancer do you provide care for in a typical month?

Presurvey

When counseling patients with endometrial cancer about the treatment implications of their molecular testing results, which of the following accurately explains the role of mismatch repair deficient (dMMR)/microsatellite instability‒high (MSI-H) status?